Teva unclear on which generics affected by Actavis buyout
Teva is unable to confirm how many generics it will take over from Actavis, following its $40.5 billion buyout of the UK manufacturing company.
Teva said its acquisition of Actavis Generics from owner Allergan yesterday (August 2) brings together "two leading generics businesses with complementary strengths".
When asked by C+D which of Actavis's more than 850 product lines would transfer over to its new owner, Teva said a full list will be published “in due course”.
As well as generics, "some" over-the-counter products are also being transferred to Teva, including Sudocrem and Infacol, it said.
"Too soon" for livery changes
It is “too soon” to anticipate any livery changes resulting from the takeover, Teva stressed.
“We are focusing our efforts on integrating the Actavis Generics business into Teva as smoothly as possible, with minimum disruption to our customers and patients,” a spokesperson told C+D.
In order for the deal to go ahead, the European Commission requires Teva to “guarantee continuity of competition” in the UK and Ireland by selling part of the Actavis business. As a result, Actavis's Barnstaple manufacturing plant and "a portfolio of generic molecules" will be sold in the "near future", Teva said.
"The remainder of Allergan's generics business in the UK and Ireland is to be integrated with Teva's," it added.